Patient handout

Hypertrophic cardiomyopathy (chronic management)

PRODUCTION

1. Your condition

This handout is for hypertrophic cardiomyopathy (chronic management). Your care team identified this based on: lv wall thickness ≥15 mm (or ≥13 mm with fh/genetics) (acc/aha 2022).

Other reasons your team may use this plan: exertional dyspnea / chest pain / syncope (acc/aha 2022); cmr with lge — fibrosis burden + scd risk (acc/aha 2022); family history of scd / known sarcomere variant (acc/aha 2022).

3. When to call your provider

Contact your care team if any of the following happen:

NSVT on Holter or syncope → ICD evaluation (ACC/AHA 2022)
NYHA III–IV refractory → septal reduction (myectomy or alcohol ablation) (ACC/AHA 2022)
AF → AC + rate/rhythm management (ACC/AHA 2022)
End-stage non-obstructive HCM with HFrEF → advanced HF center / transplant (ACC/AHA 2022)

4. When to seek emergency care

Call 911 or go to the nearest emergency room right away if you have:

HCM-RISK-SCD ≥6% / family Hx SCD / unexplained syncope / NSVT / LV thickness ≥30 / extensive LGE (ACC/AHA 2022)
Any documented AF in HCM patient regardless of CHA₂DS₂-VA (ACC/AHA 2022)
NYHA III–IV + LVOT gradient ≥50 despite mavacamten + BB/CCB + disopyramide (ACC/AHA 2022)
Pregnant patient with obstructive HCM (ACC/AHA 2022)

5. Follow-up

Sports clearance (shared decision), genetic counseling, lifelong follow-up cadence (ACC/AHA 2022)

6. Sources

Guideline: 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR HCM Guideline + 2023 ESC Cardiomyopathies Guideline + EXPLORER-HCM mavacamten trial